妇科肿瘤学试验中种族和族裔少数群体的代表性不足:对超过250项试验的分析
该研究分析了2007至2020年注册的妇科肿瘤试验,发现252项已发表结果的试验中仅99项(39.3%)报告了种族/族裔数据,且少数群体实际入组显著低于基于2010年美国人口普查的预期,尽管近年有所改善。
要点
- 已发表结果的妇科肿瘤试验中仅39.3%报告种族/族裔数据。
- 卵巢癌试验报告率最低,为32.1%。
- 少数群体入组低于预期,如卵巢癌中黑人低7倍、拉丁裔低10倍。
核心结论
- 不到一半的已发表试验报告了种族/族裔数据,现有数据显示少数群体入组显著低于基于全国人口普查数据的预期率,且调整人口规模后差异持续存在。
研究设计与样本
- 分析2007至2020年在ClinicalTrials.gov注册的妇科肿瘤研究,对已发表结果的试验按疾病部位和试验特征分析种族/族裔报告情况,并基于2010年美国人口普查数据计算预期入组进行比较。
主要发现
- 共识别2146项妇科肿瘤试验,其中252项有发表结果,99项(39.3%)报告了种族/族裔数据。
- 近期试验更可能报告数据:2007-2009年36%,2013-2015年51%,2016-2018年53%(p=0.01)。
- 卵巢癌试验报告种族/族裔数据的可能性最低(32.1% vs 39.3%,p=0.011)。
- 人口调整后入组不足:卵巢癌中黑人低7倍,卵巢癌中拉丁裔低10倍、子宫癌中低6倍,子宫癌中亚裔低2.5倍,卵巢癌中美国印第安人和阿拉斯加原住民低6倍。
- 少数群体占试验参与者比例从2007-2009年的19.6%升至2016-2018年的38.1%(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the participation of racial and ethnic minority groups (REMGs) in gynecologic oncology trials. METHODS: Gynecologic oncology studies registered on ClinicalTrials.gov between 2007 and 2020 were identified. Trials with published results were analyzed based on reporting of race/ethnicity in relation to disease site and trial characteristics. Expected enrollment by race/ethnicity was calculated and compared to actual enrollment, adjusted for 2010 US Census population data. RESULTS: 2146 gynecologic oncology trials were identified. Of published trials (n = 252), 99 (39.3%) reported race/ethnicity data. Recent trials were more likely to report these data (36% from 2007 to 2009; 51% 2013-2015; and 53% from 2016 to 2018, p = 0.01). Of all trials, ovarian cancer trials were least likely to report race/ethnicity data (32.1% vs 39.3%, p = 0.011). Population-adjusted under-enrollment for Blacks was 7-fold in ovarian cancer, Latinx 10-fold for ovarian and 6-fold in uterine cancer trials, Asians 2.5-fold in uterine cancer trials, and American Indian and Alaska Native individuals 6-fold in ovarian trials. Trials for most disease sites have enrolled more REMGs in recent years - REMGs made up 19.6% of trial participants in 2007-2009 compared to 38.1% in 2016-2018 (p < 0.0001). CONCLUSION: Less than half of trials that published results reported race/ethnicity data. Available data reveals that enrollment of REMGs is significantly below expected rates based on national census data. These disparities persisted even after additionally adjusting for population size. Despite improvement in recent years, additional recruitment of REMGs is needed to achieve more representative and equitable participation in gynecologic cancer clinical trials.
引用
- Richardson MT, Barry D, Steinberg JR, et al. Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials. Gynecol Oncol. 2023. PMID: 38096673. doi:10.1016/j.ygyno.2023.12.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。